Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients: on Behalf of the DARE-ESKD Trial

NCT05343078 is registered in ClinicalTrials.gov with University of Campinas, Brazil as lead sponsor.

NCT NCT05343078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05343078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients: on Behalf of the DARE-ESKD Trial
Lead sponsor
University of Campinas, Brazil
Phase
Phase 4
Overall status
Completed
Start date
April 25, 2022
Completion date
October 1, 2022
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal disease